Healthcare of Ontario Pension Plan Trust Fund Takes Position in Structure Therapeutics Inc. Sponsored ADR $GPCR

Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) during the fourth quarter, HoldingsChannel reports. The firm acquired 467,800 shares of the company’s stock, valued at approximately $32,535,000.

A number of other institutional investors and hedge funds have also modified their holdings of the company. CWM LLC increased its position in shares of Structure Therapeutics by 35.2% during the fourth quarter. CWM LLC now owns 480 shares of the company’s stock valued at $33,000 after purchasing an additional 125 shares during the period. HighTower Advisors LLC increased its position in shares of Structure Therapeutics by 3.6% during the fourth quarter. HighTower Advisors LLC now owns 9,320 shares of the company’s stock valued at $648,000 after purchasing an additional 320 shares during the period. State of Wyoming increased its position in shares of Structure Therapeutics by 29.7% during the fourth quarter. State of Wyoming now owns 1,761 shares of the company’s stock valued at $122,000 after purchasing an additional 403 shares during the period. PNC Financial Services Group Inc. increased its position in shares of Structure Therapeutics by 9.4% during the third quarter. PNC Financial Services Group Inc. now owns 4,828 shares of the company’s stock valued at $135,000 after purchasing an additional 413 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of Structure Therapeutics by 4.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,888 shares of the company’s stock valued at $757,000 after purchasing an additional 444 shares during the period. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Price Performance

Shares of GPCR stock opened at $43.07 on Tuesday. The firm has a market cap of $3.06 billion, a price-to-earnings ratio of -49.51 and a beta of -1.35. The stock’s fifty day simple moving average is $43.44 and its 200 day simple moving average is $57.39. Structure Therapeutics Inc. Sponsored ADR has a one year low of $15.80 and a one year high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.04. On average, research analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -1.64 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently issued reports on GPCR. Canaccord Genuity Group began coverage on Structure Therapeutics in a research report on Monday, April 27th. They set a “buy” rating and a $101.00 price objective on the stock. HC Wainwright lowered their price objective on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating on the stock in a research report on Thursday, June 11th. Citizens Jmp lowered their price objective on Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating on the stock in a research report on Friday, February 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Tuesday, April 21st. Finally, BMO Capital Markets set a $145.00 price target on Structure Therapeutics and gave the company an “outperform” rating in a research note on Tuesday, March 17th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $106.75.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.